24.10.2017 16:00:00
|
Array Biopharma To Report Financial Results For The First Quarter Of Fiscal 2018 On October 31, 2017
BOULDER, Colo., Oct. 24, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017. Ron Squarer, Chief Executive Officer, will lead the call.
Date: | Tuesday, October 31, 2017 |
Time: | 9:00 a.m. Eastern Time |
Toll-Free: | (844) 464-3927 |
Toll: | (765) 507-2598 |
Pass Code: | 94698561 |
Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/hcxcet4b
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
(303) 386-1193 | |
thaugeto@arraybiopharma.com |
View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2018-on-october-31-2017-300541497.html
SOURCE Array BioPharma Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Array BioPharma Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |